SH
Sakagami, Hiroshi
10 papers · 107 citations · 2021–2026
Publications
10
Citations
107
Years
5
Publications
| Title | Year | Type | Citations |
|---|---|---|---|
|
Design, synthesis and QSAR-based antitumor signaling pathway analysis of pyrazoline- benzenesulfonamides mediated by cytostatic G1 arrest
|
2026 | Article | 0 |
|
Microwave-assisted synthesis of indanone-based mannich base derivatives:<i> In</i><i> Silico</i> study, evaluations of dual enzyme inhibition, drug-likeness, cytotoxicity, and selectivity properties (vol 1358, 145363, 2026)
|
2026 | Correction | 0 |
|
Tumor-specific cytotoxicity of pyrazole-based chalcone derivatives in human oral squamous cell carcinoma cell lines
|
2025 | Article | 0 |
|
Indanone-based Mannich bases: Design, synthesis, in-silico molecular docking, ADME predictions and biological evaluation including carbonic anhydrases, acetylcholinesterase inhibition and cytotoxicities
|
2025 | Article | 13 |
|
Synthesis, Bioactivities, and <i>in Silico</i> Studies of Novel Benzo[<i>d</i>][1,3]Dioxole-Based Pyrazoline Sulfonamides
|
2025 | Article | 5 |
|
Biological Activities and Drug-Likeness Properties of Phenol-Based Heterocyclic Compounds
|
2024 | Article | 8 |
|
Investigation of carbonic anhydrase inhibitory effects and cytotoxicities of pyrazole-based hybrids carrying hydrazone and zinc-binding benzenesulfonamide pharmacophores
|
2022 | Article | 14 |
|
Exploring of tumor-associated carbonic anhydrase isoenzyme IX and XII inhibitory effects and cytotoxicities of the novel <i>N</i>-aryl-1-(4-sulfamoylphenyl)-5-(thiophen-2-yl)-1<i>H</i>-pyrazole-3-carboxamides
|
2021 | Article | 19 |
|
Synthesis and biological evaluation of new pyrazolebenzene-sulphonamides as potential anticancer agents and hCA I and II inhibitors
|
2021 | Article | 10 |
|
Comprehensive study on potent and selective carbonic anhydrase inhibitors: Synthesis, bioactivities and molecular modelling studies of 4-(3-(2-arylidenehydrazine-1-carbonyl)-5-(thiophen-2-yl)-1<i>H</i>-pyrazole-1-yl) benzenesulfonamides
|
2021 | Article | 38 |